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Background: A clinical study to investigate the leukotriene B4 (LTB4)-receptor antagonist BIIL 284 in cystic ﬁbrosis (CF) patients was
prematurely terminated due to a signiﬁcantly increased risk of adverse pulmonary events. We aimed to establish the effect of BIIL284 in models of
Pseudomonas aeruginosa lung infection, thereby contributing to a better understanding of what could have led to adverse pulmonary events in CF
patients.
Methods: P. aeruginosa DNA in the blood of CF patients during and after acute pulmonary exacerbations and in stable patients with non-CF
bronchiectasis (NCFB) and healthy individuals was assessed by PCR. The effect of BIIL 284 treatment was tested in an agar bead murine model of
P. aeruginosa lung infection. Bacterial count and inﬂammation were evaluated in lung and other organs.
Results:Most CF patients (98%) and all patients with NCFB and healthy individuals had negative P. aeruginosa DNA in their blood. Similarly, the
P. aeruginosa-infected mice showed bacterial counts in the lung but not in the blood or spleen. BIIL 284 treatment decreased pulmonary
neutrophils and increased P. aeruginosa numbers in mouse lungs leading to signiﬁcantly higher bacteremia rates and lung inﬂammation compared
to placebo treated animals.
Conclusions: Decreased airway neutrophils induced lung proliferation and severe bacteremia in a murine model of P. aeruginosa lung infection.
These data suggest that caution should be taken when administering anti-inﬂammatory compounds to patients with bacterial infections.
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In cystic fibrosis (CF), chronic lung infection with op-
portunistic pathogens, particularly Pseudomonas aeruginosa,by Elsevier B.V. All rights reserved.
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trophils [1] which contributes to the decline in lung function,
extensive tissue destruction [2], and the shortened life expec-
tancy [3]. Therefore, in addition to strategies that minimize
infection [4], strategies which reduce chronic inflammation
have been put forward [5]. Furthermore, episodes of acute
pulmonary exacerbations [6,7] have a detrimental effect on life
expectancy in CF [8,9]. Increased bacterial proliferation in
sputum samples from CF patients during acute pulmonary
exacerbations [10] raise the possibility that P. aeruginosa may
translocate to the bloodstream, contributing to symptoms of
acute pulmonary exacerbations. However, to date this theory
has not been adequately addressed.
To limit inflammation in CF airways, inhibition of the
leukotriene B4 (LTB4)-receptor has been tested in CF patients
using the LTB4-receptor antagonist BIIL 284 [11]. LTB4, a
dihydroxy fatty acid formed from arachidonic acid by the
5-lipoxygenase pathway, is produced mainly by activated neu-
trophils and macrophages [12]. When binding to its receptor
[13], LTB4 stimulates its own production in an autocrine
manner, thereby augmenting inflammation via NFκB [14,15].
The main biological functions of LTB4 are recruitment and
activation of inflammatory cells, not only neutrophils, but also
macrophages, monocytes, eosinophils and lymphocytes [12,16].
Thus, LTB4 has been demonstrated to be an important participant
in the pathophysiology of inflammatory diseases including CF
[17]. However, a 24 week, placebo-controlled phase II trial,
assessing the efficacy of BIIL 284 in children and adults with
CF was terminated prematurely in 2004, due to a significantly
increased risk of adverse pulmonary events in the adult patients
receiving active treatment compared to those receiving placebo
(see Konstan et al., this Journal). These adverse pulmonary events
were characterized by increased presentation of respiratory signs
and/or symptoms associated with pulmonary exacerbation and
resulted in hospital admission and/or administration of IV
antibiotics.
A potential cause for these adverse pulmonary events has
not been previously explored. We hypothesized that neutrophils
migrating into CF airways in response to chronic P. aeruginosa
infection would usually be sufficient to prevent proliferation of
bacteria in the lung and dissemination to the bloodstream.
Therefore, the inhibitory effect of BIIL 284 on neutrophil
migration and activation in CF airways could conceivably
deplete neutrophil cell numbers to such an extent that the
infecting micro-organisms could replicate in the lung and enter
the bloodstream and contribute to the symptoms of acute
pulmonary exacerbations.
Therefore, our aim was to understand the mechanism(s) by
which BIIL 284 could have induced adverse pulmonary events
in CF patients; we employed the agar bead mouse model of
lung infection model which resembles in vivo conditions in the
CF airways [18]. In the agar bead model, bacteria are protected
from an immediate neutrophil attack in the airways by the
agar beads and the microaerobic/anaerobic growth conditions
present in these beads rapidly induce a switch from a com-
pletely alginate-negative to an alginate-positive phenotype of
P. aeruginosa. The agar bead model has been previously usedas a model for chronic model of P. aeruginosa lung infection
mimicking the CF pathophysiology.
Here we show that translocation of P. aeruginosa from the
airways into the bloodstream is a rare event even during acute
pulmonary exacerbations, and may be controlled by the high
neutrophil numbers typically found in the airways of infected
CF patients. Similarly to human, bacteremia in P. aeruginosa-
infected mice does not occur in the mouse model established in
this study. However, we report that treatment of P. aeruginosa-
infected mice with high doses of BIIL 284 not only signif-
icantly decreased pulmonary neutrophil numbers but also in-
creased pulmonary P. aeruginosa numbers, leading to higher
bacteremia rates and higher lung inflammation compared to
placebo treated animals.2. Methods
2.1. Patients
To assess whether acute pulmonary exacerbations in CF
patients would lead to translocation of P. aeruginosa from
the airways to the bloodstream, we determined the relative
frequency of DNA in plasma samples from CF patients with
and without acute pulmonary exacerbations. From November
9, 2010 to November 30, 2012, 44 adolescent and adult CF
patients (21 females, 23 males, mean age: 35.7 years) were
recruited for a prospective screening study for P. aeruginosa
DNA in blood samples. Patients were eligible for enrollment if
they had CF that had been diagnosed according to genetic test,
an age ≥18 years, chronic P. aeruginosa lung infection and an
acute pulmonary exacerbation, defined by at least 4/12 positive
Fuchs criteria [6]. Patients were excluded if they had an acute
asthmatic complication. The primary aim of the study was to
determine the relative frequency of P. aeruginosa DNA in
plasma samples from CF patients with and without acute
pulmonary exacerbation. Blood samples were stored at −20 °C
prior to examination. The patients attended the Comprehensive
CF Centre (CCFC) Tübingen-Stuttgart at the clinic
Schillerhöhe, Robert-Bosch Krankenhaus, Gerlingen, Germany
(n = 1) and the Universitätsklinikum Frankfurt, Frankfurt,
Germany (n = 43). Additionally, blood samples from 17 CF
patients (10 females, 7 males, mean age: 33.3 years) attending
the Queen′s University Belfast, Northern Ireland (n = 11) and
the Case Western Reserve University, UH Rainbow Babies
& Children's Hospital, Cleveland, USA (n = 6) and blood
samples from 10 patients with non-CF bronchiectasis,
suffering from chronic P. aeruginosa lung infection (8
females, 2 males, mean age: 59.1 years) attending the Royal
Brompton Hospital, London, UK, and from 17 healthy
individuals (9 females, 8 males, mean age: 34.3 years) from
the Queen′s University Belfast, Northern Ireland [7] and the
Institute of Medical Microbiology and Hygiene,
Universitätsklinikum Tübingen, Tübingen, Germany (n = 10),
were examined for P. aeruginosa DNA. Informed consent was
obtained from all patients and the study protocols were approved
by the institutional review boards in the respective jurisdictions.
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DNA was extracted from whole blood samples using the
Qiagen DNeasy Maxi kit (Qiagen) according to the manu-
facturer's instructions and stored at −20 °C until required.
P. aeruginosa DNA was quantitated in blood samples from
CF patients, patients with non-CF bronchiectasis and healthy
individuals using qPCR TaqMan assays based on the PA4331
gene, which is ubiquitously present in a collection of 117
isolates from 14 CF patients and therefore a stable marker of
P. aeruginosa. A standard curve was used to determine the
absolute copy number of the target. DNA was amplified in
duplicate using an iCycler (Bio-Rad) with cycle threshold
values obtained using iCycler CFX Manager 1.6. Baseline
cycles and threshold positions were manually adjusted. The
RT-PCR mixture (15 μl final volume) contained: 1× KAPA
PROBE FAST Universal qPCR Master Mix (Mix contains
Taq Hot Start DNA polymerase, qPCR Buffer, dNTPs, MgCl2
and stabilizers) (peQlab, Erlangen, Germany), 0.3 μM Primer
PA4331 forward (5′-GTGTTGCAGCCTTTCGATCC3′-),
0.3 μM Primer PA4331 reverse (5′-AACTCCAGCCATGG
GTCCTC 3′-), and 0.3 μM qPCR PA4331 Probe (5′-FAM
GCAGCACCTGCTGCTGTGGA 3′-TAM) (Eurofins MWG
Operon, Ebersberg, Germany). PCR conditions were 3 min
at 95 °C, followed by 50 cycles of 10 s at 95 °C and 30 s at
64 °C. Fluorescent data were collected at the 64 °C step.
2.3. Mouse model, bacterial numbers and markers of
lung inflammation
Groups of 6–14 C57Bl/6 male mice (Charles River,
Sulzfeld, Germany; Charles River, Calco, Italy), 8–10 weeks
old (24–26 g), received orally by gavage 100 μl of suspensions
containing 0.3, 50 or 100 mg/kg body weight of BIIL 284
(Novartis, Horsham, UK) in phosphate buffered saline (PBS),
pH 7.2, supplemented with polyethylene glycol (PEG) 200 in a
1:1 (vol/vol) ratio. Control mice were treated with placebo. One
hour later the mice were injected intratracheally with either
50 μl of PBS, or 50 μl of a suspension of P. aeruginosa, strain
PAO1, containing 5 × 105–5 × 107 colony forming units (cfu),
embedded in agar beads [18]. After 24 h, mice were killed, with
an overdose of CO2. Lungs and spleens were removed and
homogenized in 1 ml PBS with Ca2+/Mg2+ containing the
protease inhibitor PMSF (Sigma). Bacterial counts (cfu) were
determined in total lung and spleen homogenates as well as in
blood by routine dilution methods on agar plates. Additionally, at
this time point, neutrophil and macrophage numbers were assessed
in bronchoalveolar (BAL) fluids. BAL was performed three times
using 1 ml of RPMI 1640 (Complete tablets, Roche Diagnostic)
with a 22-gauge venous catheter. Total cells present in the BAL
fluid were counted and a differential cell count was performed on
cytospins stained with Diff Quick (Dade, Biomap, Italy). BALF
were serially diluted 1:10 in PBS and plated for bacterial counts.
BALF were then centrifuged and supernatants were collected for
quantification of total protein content using the Bradford assay
(Bio-Rad). After erythrocyte lysis with ACK lysis solution pH 7.2
(NH4Cl 0.15 M, KHCO3 10 mM, EDTA 0.1 mM), cells werere-suspended in cetyltrimethylammonium chloride 0.5% (CTAC,
Sigma Aldrich) (250 μl/mouse) and centrifuged.
Murine cytokines (IL-1β, KC, MIP-2 and JE) were
measured by ELISA (R&D DuoSet ELISA Development
System, USA) according to manufacturer's instructions in
supernatant fluids of total lung homogenates after centri-
fugation (14,000 rpm/30 min/4 °C). MIP-2 and KC affect
neutrophil recruitment, while JE promotes monocyte/macro-
phage recruitment and IL-1β is involved in inflammation and
cell death.
To localize P. aeruginosa in lungs of untreated and BIIL
284 treated C57Bl/6 mice, infected with P. aeruginosa as
described above, mice from each group were sacrificed after
24 h, the lungs were removed en bloc, rinsed in PBS and
prepared for detection of P. aeruginosa by indirect immuno-
fluorescence as described previously [2], using a specific rabbit
antibody against whole cell P. aeruginosa. The animal study
protocols were reviewed and approved by the Animal ethics
committee of the H.S. Raffaele Animal Care and Use Committee,
Milano, Italy.
2.4. Statistical analysis
CFU data, cell count and cytokines are expressed as mean ±
SEM. Two-tailed Student's t and Chi-square test was used.
p ≤ 0.05 was considered significant. Kendall's rank-correlation,
tau was used to assess the relationship between the ordinal
variable BIIL 284 and the continuous variable ratio (cfu/
neutrophils) [19].
3. Results
3.1. Assessment of P. aeruginosa bacteremia in patients with
acute pulmonary exacerbations and in the mouse model
First, we assessed the incidence of bacteremia in P.
aeruginosa chronically infected CF patients during episodes
of acute pulmonary exacerbation (n = 17) or when clinically
stable (n = 44) by employing qPCR for the gene PA4331 in
61 CF patients. Regardless of whether clinically stable or
presenting with an acute pulmonary exacerbation, all but
one blood sample from CF patients (60/61; 98%) yielded
negative qPCR for P. aeruginosa (Fig. 1). The single qPCR
positive CF patient who had a forced expiratory volume in
1 s, (FEV1%), predicted, of 44%, and did not recover
clinically following treatment of an acute pulmonary
exacerbation, had 4 × 103 cells of P. aeruginosa per ml in
his blood. Mean lung function, measured as FEV1%, was
56% (range: 21%–76.1%) in the 17 CF patients suffering
from acute pulmonary exacerbation and 59% (range: 26%–
116%) in the 44 clinically stable CF patients. These data reveal
that even in CF patients with severe lung disease P. aeruginosa
is not translocating from the airways to the circulation. Similarly,
we were unable to detect P. aeruginosa DNA by qPCR in blood
samples from a cohort of 10 patients with non-CF bronchiectasis
and P. aeruginosa lung infection and in blood samples from 17
healthy individuals.
Positive control
CF sample
Fig. 1. Bacterial quantification of P. aeruginosa DNA in the blood of a CF patient. TaqMan quantitative PCR was performed on DNA extracts of blood samples from
CF patients, patients with non-CF bronchiectasis and healthy individuals. A. Agarose gel with qPCR product results of 16 CF patients revealing one positive sample
with the amplification of the 200 bp PA4331. 17: positive control (plasmid DNA including PA 4331, spiked with human DNA), 18: negative control (human DNA)
19: water control; B. qPCR amplification curves of the PA4331 and controls in the blood sample from CF patient #4. Red bar: cut-off of the assay.
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to simulate lung infection of CF patients and determine the
effect of BILL 284 on bacterial counts and inflammation. We
assessed respiratory infection and bacteremia by challenging
via intratracheal administration C57Bl/6 mice with different
doses of P. aeruginosa PAO1 strain (Table 1S). A dose of
5 × 107 cfu of P. aeruginosa was found to cause high mortality
during the first 3 days (100%) due to high bacterial load in
the airways and bloodstream. Doses of 5 × 106 and 5 × 105
decreased mortality to 25 and 0%, respectively, while maintained
chronic infection at 7 days (25%). Since bacteremia did not
occur in mice treated with P. aeruginosa 5 × 105 cfu, this dose
was selected for testing the effect of BILL 284 treatment as
described below.3.2. BIIL 284 decreases numbers of phagocytic cells in lungs of
mice infected with P. aeruginosa
To assess whether BIIL 284, administered orally to C57Bl/6
mice in doses of 0.3, 50 or 100 mg/kg body weight, would
decrease neutrophil and macrophage numbers in P. aeruginosa
infected airways, we challenged groups of six to eight mice by
intratracheal administration with 5 × 105 cfu of P. aeruginosa
1 h after BIIL 284 oral administration. Twenty-four hours
after treatment, neutrophil numbers had decreased ≥50% in
BAL fluids compared to untreated control animals. Untreated
mice had a mean influx of 3.42 × 106 neutrophils in their
P. aeruginosa infected lungs; however treatment with 0.3 mg/kg,
50 mg/kg or 100 mg/kg BIIL 284 resulted in a significantdecrease in neutrophils to 1.37 × 106, 1.26 × 106 and 1.55 × 106
neutrophils per ml BAL, respectively (Fig. 2A). We also ob-
served a trend towards decreases in macrophage numbers, though
this was not significant compared to control animals (p b 0.05)
(Fig. 2B). The data demonstrated the expected biological efficacy
of BIIL 284 to inhibit neutrophil migration to pulmonary sites of
infection.3.3. BIIL 284 allows growth of P. aeruginosa in lungs of
infected mice and causes bacteremia at high doses
Next we determined whether the effect of BIIL 284 on
neutrophil levels in the lungs would affect the growth of
P. aeruginosa in the infected mouse lung. P. aeruginosa cfu
were determined in groups of seven or 14 mice challenged
with 5 × 105 cfu of P. aeruginosa and treated with 0.3, 50
or 100 mg/kg body weight of BIIL 284, respectively. While
bacterial numbers remained stable in total lung homogenates
of animals treated with 0.3 mg/kg body weight of BIIL 284
after 24 h, P. aeruginosa cfu increased significantly (p b 0.01)
when 50 or 100 mg/kg body weight of BIIL 284 was ad-
ministered compared to untreated control animals (Fig. 2C).
A significant correlation between the ratio of P. aeruginosa
cfu/neutrophils and BIIL 284 concentration was found (Ϯ =
0.5262; p = 0.017) (Fig. 2D).
To assess whether excessive bacterial growth would lead to
sepsis, we also determined P. aeruginosa levels in other mouse
organs. Two of 12 BIIL 284-untreated animals (17%) had
between 101 and 102 cfu of P. aeruginosa in the blood and
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Fig. 2. BIIL 284 treatment changes the ratio between phagocytic cells and bacteria in lungs of mice infected with P. aeruginosa. A, B, BIIL 284 treatment decreases
neutrophil but not macrophage numbers in bronchoalveolar lavage fluids (BALF) of infected mice. Groups of six to eight mice were challenged intratracheally with
5 × 105 cfu of P. aeruginosa and 1 h thereafter with different doses of BIIL 284. Neutrophil (A) and macrophage (B) numbers were determined in BALF of infected
animals and uninfected controls by routine methods. C, BIIL 284 promotes growth of P. aeruginosa in lungs of infected mice. Groups of seven to 14 mice
were challenged with different doses of BIIL 284 1 h before intratracheal challenge with 5 × 105 cfu of P. aeruginosa and bacterial colony forming units (cfu)
were determined in total lung tissues of infected and uninfected animals after 24 h using routine methods. D, BIIL 284 treatment changes the ratio of P. aeruginosa
cfuscfu/neutrophils. Kendall's rank-correlation, † was used to assess the relationship between the ordinal variable BIIL 284 and the continuous variable ratio (cfu/
neutrophils). *p ≤ 0.05; **p b 0.01.
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body weight of BIIL 284, cfu between 102 and 103 cfu were
detected in the blood and spleens (Table 2, Table 3).
Furthermore, in 5/6 (83%) animals treated with 50 mg/kg of
BIIL 284, between 102 and 103 cfu were detected and in 11/14
(78%) animals treated with 100 mg/kg of BIIL 284 between
102 and 103 were detected (Table 2S, Table 3S). Thus, BIIL 284
treatment significantly increased the risk of sepsis in a dose de-
pendent manner when compared to untreated mice (0.3 mg/kg vs
untreated: p = 0.1; 50 mg/kg: p = 0.01; 100 mg/kg: p = 0.005).3.4. BIIL 284 promotes increased cytokine expression in lungs
of infected mice and allows P. aeruginosa to reach the
airway epithelium
We determined whether the increased bacterial growth in
BIIL 284-treated mice would stimulate respiratory epithelial
cells to increase production of cytokines and chemokines. At
doses of 50 and 100 mg/kg body weight of BIIL 284, 24 h after
challenge, IL-1β, KC (equivalent to IL-8 in humans), MIP-2
and JE were found all to be significantly increased in lung homo-
genates from treated/infected mice versus untreated/infected mice.
At doses of 0.3 mg/kg body weight of BIIL 284, only IL-1β and
JE were significantly increased (Fig. 3). Next, we localized the
pathogen in infected airways by indirect immunofluorescence.
While in untreated mice P. aeruginosawas detected exclusively inthe bronchial lumen (Fig. 4), treatment with a single dose of
50 or 100 mg/kg of BIIL 284 led to additional detection of
P. aeruginosa at the bronchial epithelium as well as in the
alveoli (Fig. 4). These data suggest that immunosuppression
allows P. aeruginosa to elicit increased cytokine expression
from airway epithelial cells and to enter the bloodstream via
the bronchial epithelium or the alveoli. Taken together, our
data demonstrate that immune suppression by BIIL 284 at
high doses can provoke inflammation and bacteremia in mice
whose airways are infected with P. aeruginosa.4. Discussion
The oral long-acting LTB4 receptor antagonist BIIL 284
has been shown previously to inhibit LTB4-induced neutrophil
cell activation as monitored by intracellular Ca release, and
to inhibit LTB4-induced neutrophil chemotaxis, possibly by
inhibition of expression of the integrin Mac-1 (αMβ2, CR3)
[20]. In a previous study, a single oral dose of 0.3 mg/kg p.o.
completely inhibited LTB4-induced Mac-1 expression over 24 h
in monkeys [11]. Because Mac-1 also mediates phagocytosis of
bacteria and other particles [21], BIIL 284 treatment most probably
also interferes with this neutrophil function.
Here we demonstrate that administration of BIIL 284 to
mice at a dose of 0.3 to 100 mg/kg body weight significantly
reduces the numbers of phagocytic cells in airways and lung
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Fig. 3. BIIL 284 treatment increases lung inflammation infected mice. A, BIIL 284 promotes increased cytokine expression in lungs of infected mice. The chemokines
IL-1β, KC, MIP-2 and JE were quantitatively determined by ELISA in lung homogenates of uninfected mice, treated with a single dose of 100 mg/kg BIIL 284, and
in untreated infected mice (CTR) and in infected mice, treated with the doses of 0.3, 50 and 100 mg/kg BIIL 284. *p ≤ 0.05; **p b 0.01; p b 0.001.
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previous results with this anti-inflammatory drug [11,21].
Moreover, reducing the neutrophil influx into P. aeruginosa
infected airways of mice by ≥50% highlighted the extreme
potency of this compound.
In the presence of an established P. aeruginosa infection,
the reduction in neutrophil numbers in conjunction with the
established down-regulation of Mac-1 (CR3) by BIIL 284 was
associated with a profound proliferation of P. aeruginosa in
the lungs of the infected mice, as well as entry of this pathogen
into the bloodstream. Our data also demonstrated that BIIL
treatment resulted in increased pro-inflammatory cytokine
production in this mouse model, suggesting that the bacterial
proliferation led to stimulation of lung epithelial cells to
enhance cytokine production, probably via Toll-like receptor
activation. This notion is also supported by our finding that
P. aeruginosa cells were detectable in the lung periphery of
BIIL 284 treated animals but not in untreated, infected animals
and that BIIL 284 treatment resulted in increased sepsis rates in
animals treated with 50 and 100 mg/kg BIIL 284. Both KC and
MIP-2 are selectively chemotactic for neutrophils and expressed
in various cell types including lung epithelial cells [22]. Their
up-regulation during BIIL 284 treatment creates the paradoxical
situation that an anti-inflammatory drug induces inflammation in
the infected murine airways. In contrast to BIIL 284, the macrolide
azithromycin given at a concentration of 20 mg/kg has been
shown to reduce airway neutrophil numbers, inflammatory
cytokine levels and P. aeruginosa cell numbers significantly in a
similar model of murine lung infection [23].
Our results may help explain the termination of a phase II
study in which the efficacy and safety of BIIL 284 wereevaluated in patients with CF. In this study, pediatric subjects
received 1.75 mg/kg BIIL 284 for a median of 102 days, while
adults received 1.23 mg/kg or 2.35 mg/kg BIIL 284 for a
median of 149 days. The study was terminated due to a
significantly higher incidence of adverse pulmonary events in
the treatment group. Although it is not clear at present how and
whether these adverse pulmonary events are related to sepsis,
proliferation of bacterial cell numbers is a consistent finding in
such episodes [8]. Because BIIL 284 inhibited Mac-1 expression
in monkey studies for more than 24 h [11], the repeated daily BIIL
284 dosing schedule in the phase II clinical study may have led to
an accumulation of functional impairments in neutrophils during
the study period.
Here we have shown that translocation of P. aeruginosa
from the airways into the bloodstream is a rare event in CF and
NCFB, and may be controlled by the neutrophil response to
chronic bacterial lung infection. Similarly to humans, we also
demonstrated in a mouse model of P. aeruginosa lung infection,
optimized to test the effect of BIIL 284, that bacteremia did not
occur. Based on our animal data, we propose that adverse pul-
monary events in the BIIL 284 CF patient study may have been
caused by unrestrained bacterial multiplication and virulence,
followed by septic episodes due to reduced neutrophil activity and
cell numbers. Unfortunately, the causal relationship between
neutrophil response and sepsis in the original BIIL 284 study
cannot be demonstrated directly, due to the lack of blood samples
from CF patients.
A number of effector defense mechanisms have been im-
plicated in the host fight against P. aeruginosa, including im-
mune cells, as macrophages and natural killer cells, or molecules,
as antimicrobial peptides. However, neutrophils have been shown
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Fig. 4. BIIL 284 treatment increases P. aeruginosa translocation via the alveoli in infected mice. BIIL 284 treatment allows P. aeruginosa to reach the airway
epithelium. P. aeruginosa was stained with a specific antibody in 5 μm lung tissue sections of infected mice treated with a single dose of 100 mg/kg BIIL 284 (A, B),
or 50 mg/kg of BIIL 284 (C, D) or untreated animals (E, F). Br: Bronchus, P: Periphery, S: septa, red color and arrow: P. aeruginosa. Original magnifications: A, C, E
×100; insets B, D, F ×1000.
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infection [24]. Our data support the conclusions of others [25] that
a critical neutrophil concentration (CNC) is necessary to control
bacterial proliferation: for example for killing ~5 × 107 cfu of
Escherichia coli, a CNC of ~4 × 106 neutrophils is needed [25].
Clearly this CNC was not reached during treatment of infected
mice with 100 mg/kg BIIL 284, where only 1.55 × 106
neutrophils are confronted with ~5 × 107 cfu of P. aeruginosa.
In contrast, in untreated animals 3.42 × 106 neutrophils are con-
fronted with ~2 × 106 cfu of P. aeruginosa. In the latter case,
septic episodes were significantly lower than those in BIIL 284
treated animals. Our results revealing that P. aeruginosa does not
enter the bloodstream in chronically infected CF patients under
clinically stable conditions or under conditions of acute pulmonary
exacerbations therefore demonstrate the importance of the con-
siderable neutrophil influx into the infected CF airways. Only
one out of 61 CF blood samples yielded a positive qPCR forP. aeruginosa. Thus, P. aeruginosa bacteremia is a rare event
even in CF patients with severe lung disease. This notion is also
true for patients with NCFB infected with P. aeruginosa.
Taken together, these results show that caution should be
taken when administering potent anti-inflammatory compounds
as there is a potential to suppress the immune system thus
increasing the risk of exacerbation in patients with acute or
chronic infections.
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